The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation
Abstract
Injectable, long-acting depot formulations based on poly(lactide-co-glycolide) (PLGA) have been used clinically since 1989. Despite 30 years of development, however, there are only 19 different drugs in PLGA formulations approved by the U.S. Food and Drug Administration (FDA). The difficulty in developing depot formulations stems in large part from the lack of a clear molecular understanding of PLGA polymers and a mechanistic understanding of PLGA microparticles formation. The difficulty is readily apparent by the absence of approved PLGA-based generic products, limiting access to affordable medicines to all patients. PLGA has been traditionally characterized by its molecular weight, lactide:glycolide (L:G) ratio, and end group. Characterization of non-linear PLGA, such as star-shaped glucose-PLGA, has been difficult due to the shortcomings in analytical methods typically used for PLGA. In addition, separation of a mixture of different PLGAs has not been previously identified, especially when only their L:G ratios are different while the molecular weights are the same. New analytical methods were developed to determine the branch number of star-shaped PLGAs, and to separate PLGAs based on L:G ratios regardless of the molecular weight. A deeper understanding of complex PLGA formulations can be achieved with these new characterization methods. Such methods are important for further development of not only PLGA depot formulations with controllable drug release kinetics, but also generic formulations of current brand-name products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Dynamics of Capillary Flow
Washburn, E. W. (1921) · Physical Review · doi:10.1103/physrev.17.273 · Cited by 7,141
Contact Angle and Wetting Properties
Yuan, Y., & Lee, T. R. (2013) · Springer Series in Surface Sciences · doi:10.1007/978-3-642-34243-1_1 · Cited by 1,396
The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—A review
Fredenberg, S., Wahlgren, M., Reslow, M., & Axelsson, A. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.049 · Cited by 1,286
(2013) · Springer Series in Surface Sciences · doi:10.1007/978-3-642-34243-1 · Cited by 736
Controlled drug delivery systems: Past forward and future back
Park, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.054 · Cited by 720
Self-citationPharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant
Chang-Lin, J.-E., Attar, M., Acheampong, A. A., Robinson, M. R., Whitcup, S. M., Kuppermann, B. D., & Welty, D. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5285 · Cited by 590
Control of encapsulation efficiency and initial burst in polymeric microparticle systems
Yeo, Y., & Park, K. (2004) · Archives of Pharmacal Research · doi:10.1007/bf02980037 · Cited by 567
Self-citationAn overview of clinical and commercial impact of drug delivery systems
Anselmo, A. C., & Mitragotri, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.053 · Cited by 520
Issues in long-term protein delivery using biodegradable microparticles
Ye, M., Kim, S., & Park, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.011 · Cited by 386
Self-citationControlled Drug Delivery: Historical perspective for the next generation
Yun, Y. H., Lee, B. K., & Park, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.005 · Cited by 378
Self-citation
Cited by
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020) · Nanomaterials · doi:10.3390/nano10071403 · Cited by 1,061
Evolution of drug delivery systems: From 1950 to 2020 and beyond
Park, H., Otte, A., & Park, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.030 · Cited by 475
Self-citationPhenomenology of the Initial Burst Release of Drugs from PLGA Microparticles
Yoo, J., & Won, Y.-Y. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01228 · Cited by 392
Zero-order drug delivery: State of the art and future prospects
Laracuente, M.-L., Yu, M. H., & McHugh, K. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.020 · Cited by 384
PLGA-Based Composites for Various Biomedical Applications
Rocha, C. V., Gonçalves, V., da Silva, M. C., Bañobre-López, M., & Gallo, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042034 · Cited by 350
Machine learning directed drug formulation development
Bannigan, P., Aldeghi, M., Bao, Z., Häse, F., Aspuru-Guzik, A., & Allen, C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.016 · Cited by 335
Systemic Review of Biodegradable Nanomaterials in Nanomedicine
Su, S., & Kang, P. M. (2020) · Nanomaterials · doi:10.3390/nano10040656 · Cited by 312
Recent advances in the formulation of PLGA microparticles for controlled drug delivery
Lagreca, E., Onesto, V., Di Natale, C., La Manna, S., Netti, P. A., & Vecchione, R. (2020) · Progress in Biomaterials · doi:10.1007/s40204-020-00139-y · Cited by 284
Vlachopoulos, A., Karlioti, G., Balla, E., Daniilidis, V., Kalamas, T., Stefanidou, M., Bikiaris, N. D., Christodoulou, E., Koumentakou, I., Karavas, E., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020359 · Cited by 277
Gao, J., Karp, J. M., Langer, R., & Joshi, N. (2023) · Chemistry of Materials · doi:10.1021/acs.chemmater.2c03003 · Cited by 272
Recent Applications of PLGA in Drug Delivery Systems
Yang, J., Zeng, H., Luo, Y., Chen, Y., Wang, M., Wu, C., & Hu, P. (2024) · Polymers · doi:10.3390/polym16182606 · Cited by 268
Lo, C. H., & Zeng, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00362-0 · Cited by 117
“Food and Drug Administration as injectable depot formulations such as microparticle [92], although PLGA-based NPs have not been approved for usage and the regulatory hurdles remain to be crossed.”
BackgroundFundamental insights in PLGA degradation from thin film studies
Machatschek, R., & Lendlein, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.044 · Cited by 73
Mayer, J. B., Patil, S. M., Shin, S.-H., Yoo, J., & Won, Y.-Y. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c00419 · Cited by 38
Miles, C. E., Bernstein, A. D., Osborn Popp, T. M., Murthy, N. S., Nieuwkoop, A. J., & Gormley, A. J. (2021) · ACS Applied Polymer Materials · doi:10.1021/acsapm.1c01254 · Cited by 20
History, introduction, and properties of PLGA as a drug delivery carrier
Yurtdaş Kırımlıoğlu, G. (2023) · Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for Drug Delivery · doi:10.1016/b978-0-323-91215-0.00001-7 · Cited by 9
Metadata
- Authors
- Park, K., Skidmore, S., Hadar, J., Garner, J., Park, H., Otte, A., Soh, B. K., Yoon, G., Yu, D., Yun, Y., Lee, B. K., Jiang, X., & Wang, Y.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 304
- Pages
- 125-134
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2943940643
- Cited by
- 404
- References
- 40
- FWCI
- 15.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.